Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB3 | P13945 | 1/20 | 0.49 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.49 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.46 |
| ▸ | CTSS | P25774 | 1/20 | 0.41 |
| ▸ | CTSB | P07858 | 2/20 | 0.37 |
| ▸ | PPP3CB | P16298 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16496452 | 1.00 | ADRB3 (0.49) | ADRB3ADRA2BADRA2CCYP3A4CTSS | |
| SCHEMBL16496453 | 1.00 | ADRB3 (0.49) | ADRB3ADRA2BADRA2CCYP3A4CTSS | |
| SCHEMBL6875247 | 0.95 | ADRB3 (0.55) | ADRB3ADRA2BADRA2CCYP3A4CTSS | |
| SCHEMBL6876793 | 0.95 | ADRB3 (0.55) | ADRB3ADRA2BADRA2CCYP3A4CTSS | |
| SCHEMBL16496404 | 0.95 | ADRB3 (0.55) | ADRB3ADRA2BADRA2CCYP3A4CTSS | |
| SCHEMBL6877593 | 0.94 | CYP3A4 (0.48) | ADRB3ADRA2BADRA2CCYP3A4CTSS | |
| SCHEMBL16495610 | 0.94 | CYP3A4 (0.48) | ADRB3ADRA2BADRA2CCYP3A4CTSS | |
| SCHEMBL16495510 | 0.92 | ADRB3 (0.47) | ADRB3ADRA2BADRA2CCYP3A4CTSS | |
| SCHEMBL6878914 | 0.92 | ADRB3 (0.47) | ADRB3ADRA2BADRA2CCYP3A4CTSS | |
| SCHEMBL16495509 | 0.92 | ADRB3 (0.47) | ADRB3ADRA2BADRA2CCYP3A4CTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011063502-A1 | HEPATITIS C INHIBITOR COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-06-03 | — | — | WO | disclosed |